A class action lawsuit has been filed against Aardvark Therapeutics (AARD) alleging misleading statements about the safety of its lead drug ARD-101. The class period runs from the Feb 13, 2025 IPO through May 14, 2026. Lead plaintiff deadline is Oct 13, 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
